학술논문
Daro-PET: A phase 2 trial of darolutamide as a prostate-specific membrane antigen (PSMA) expression enhancer in patients with localized prostate cancer.
Document Type
Article
Author
Source
Journal of Clinical Oncology; 2024 Supplement 4, Vol. 42, pTPS348-TPS348, 97p
Subject
Language
ISSN
0732183X